Results 41 to 50 of about 12,575 (207)

Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients

BMC Infectious Diseases, 2017
Background Atazanavir/ritonavir and darunavir/ritonavir are common protease inhibitor-based regimens for treating patients with HIV. Studies comparing these drugs in clinical practice are lacking.
Tony Antoniou, Leah Szadkowski, Sharon Walmsley, Curtis Cooper, Ann N. Burchell, Ahmed M. Bayoumi, Julio S. G. Montaner, Mona Loutfy, Marina B. Klein, Nima Machouf, Christos Tsoukas, Alexander Wong, Robert S. Hogg, Janet Raboud, The Canadian Observational Cohort (CANOC) collaboration   +14 more
doaj   +1 more source

Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study

Frontiers in Medicine, 2021
Background: Protease inhibitors have been considered as possible therapeutic agents for COVID-19 patients.Objectives: To describe the association between lopinavir/ritonavir (LPV/r) or darunavir/cobicistat (DRV/c) use and in-hospital mortality in COVID ...
Augusto Di Castelnuovo, Simona Costanzo, Andrea Antinori, Nausicaa Berselli, Lorenzo Blandi, Marialaura Bonaccio, Raffaele Bruno, Raffaele Bruno, Roberto Cauda, Roberto Cauda, Alessandro Gialluisi, Giovanni Guaraldi, Lorenzo Menicanti, Marco Mennuni, Ilaria My, Agostino Parruti, Giuseppe Patti, Stefano Perlini, Stefano Perlini, Francesca Santilli, Carlo Signorelli, Giulio G. Stefanini, Alessandra Vergori, Walter Ageno, Luca Aiello, Piergiuseppe Agostoni, Piergiuseppe Agostoni, Samir Al Moghazi, Rosa Arboretti, Filippo Aucella, Greta Barbieri, Martina Barchitta, Alessandro Bartoloni, Carolina Bologna, Paolo Bonfanti, Paolo Bonfanti, Lucia Caiano, Laura Carrozzi, Antonio Cascio, Giacomo Castiglione, Mauro Chiarito, Arturo Ciccullo, Antonella Cingolani, Antonella Cingolani, Francesco Cipollone, Claudia Colomba, Crizia Colombo, Francesco Crosta, Giovanni Dalena, Chiara Dal Pra, Gian Battista Danzi, Damiano D'Ardes, Katleen de Gaetano Donati, Francesco Di Gennaro, Giuseppe Di Tano, Gianpiero D'Offizi, Tommaso Filippini, Francesco Maria Fusco, Carlo Gaudiosi, Ivan Gentile, Giancarlo Gini, Elvira Grandone, Gabriella Guarnieri, Gennaro L. F. Lamanna, Giovanni Larizza, Armando Leone, Veronica Lio, Angela Raffaella Losito, Gloria Maccagni, Stefano Maitan, Sandro Mancarella, Rosa Manuele, Massimo Mapelli, Massimo Mapelli, Riccardo Maragna, Riccardo Maragna, Lorenzo Marra, Giulio Maresca, Claudia Marotta, Franco Mastroianni, Maria Mazzitelli, Alessandro Mengozzi, Francesco Menichetti, Jovana Milic, Filippo Minutolo, Beatrice Molena, R. Mussinelli, Cristina Mussini, Maria Musso, Anna Odone, Marco Olivieri, Emanuela Pasi, Annalisa Perroni, Francesco Petri, Biagio Pinchera, Carlo A. Pivato, Venerino Poletti, Claudia Ravaglia, Marco Rossato, Marianna Rossi, Anna Sabena, Francesco Salinaro, Vincenzo Sangiovanni, Carlo Sanrocco, Laura Scorzolini, Raffaella Sgariglia, Paola Giustina Simeone, Michele Spinicci, Enrico Maria Trecarichi, Giovanni Veronesi, Roberto Vettor, Andrea Vianello, Marco Vinceti, Marco Vinceti, Elena Visconti, Laura Vocciante, Raffaele De Caterina, Licia Iacoviello, Licia Iacoviello, The COVID-19 RISK and Treatments (CORIST) Collaboration   +119 more
doaj   +1 more source

Switching to a NRTI-free 2 drug regimen (2DR) –a sub-analysis of the 48 weeks DUALIS study on metabolic and renal changes

HIV Research & Clinical Practice, 2022
Background/Aims: Switching from a three-drug regimen (3DR: boosted darunavir [bDRV] and two nucleoside reverse transcriptase inhibitors [NRTIs]) to a two-drug regimen (2DR: bDRV and dolutegravir [DTG]) demonstrated non-inferiority with regard to viral ...
Malte Monin, Tim Kümmerle, Jochen Schneider, Christiane Cordes, Hans Heiken, Hans-Jürgen Stellbrink, Ivanka Krznaric, Stefan Scholten, Björn Jensen, Heiko Jessen, Wilfried Obst, Petra Spornraft-Ragaller, Pavel Khaykin, Annamaria Balogh, Eva Wolf, Helen Bidner, Christoph D. Spinner, Christoph Boesecke, on behalf of the DUALIS STUDY GROUP   +18 more
doaj   +1 more source

Pharmacotherapy update: treatment of HIV-infection with Darunavir [PDF]

, 2010
Darunavir is an oral peptidomimetic HIV-1 protease inhibitor with antiretroviral activity against wild type HIV strains and HIV strains with protease inhibitor mutations. Ritonavir-boosted darunavir is rapidly absorbed and it has a higher bioavailability
G.V. Zuccotti, V. Manfredini, A. Viganò, V. Giacomet, C. Mameli   +4 more
core   +1 more source

Efficacy and safety of darunavir and etravirine in an antiretroviral multi-experienced youth with vertically HIV-1 infection

European Journal of Medical Research, 2009
Multiclass-drug resistance, often caused by poor treatment compliance, is a challenging problem in all categories of HIV-infected patients. Selective pressure is higher in youth for both biological and behavioral reasons.
Rosso R, Bernardini C, Bruzzone B, Secondo G, Icardi G, Viscoli C, Di Biagio A   +6 more
doaj   +1 more source

Characteristics, complexation and analytical methods of darunavir [PDF]

, 2014
What is it? Darunavir is a protease inhibitor used in the treatment of HIV infection. It is an important drug of therapy cocktail for patients infected with the virus.
Salgado, Hérida Regina Nunes, Kogawa, Ana Carolina   +1 more
core   +4 more sources

Herb-Drug Interaction between Echinacea purpurea and Darunavir-Ritonavir in HIV-Infected Patients [PDF]

, 2011
The aim of this open-label, fixed-sequence study was to investigate the potential of Echinacea purpurea , a commonly used botanical supplement, to interact with the boosted protease inhibitor darunavir-ritonavir.
Eugenia Negredo, Cristina Miranda, Marta Valle, José Moltó, Bonaventura Clotet, Samandhy Cedeño, Manuel José Barbanoj   +6 more
core   +1 more source

The structural, dynamic, and thermodynamic basis of darunavir resistance of a heavily mutated HIV-1 protease using molecular dynamics simulation

Frontiers in Molecular Biosciences, 2022
The human immunodeficiency virus type 1 protease (HIV-1 PR) is an important enzyme in the life cycle of the HIV virus. It cleaves inactive pre-proteins of the virus and changes them into active proteins. Darunavir (DRV) suppresses the wild-type HIV-1 PR (
Yaser Shabanpour, Sharareh Sajjadi, Esmaeil Behmard, Parviz Abdolmaleki, Amir Homayoun Keihan   +4 more
doaj   +1 more source

Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir [PDF]

, 2017
Cobicistat and ritonavir have different inhibitory profiles for drug transporters that could impact the distribution of co-administered drugs. We compared darunavir concentrations in CSF when boosted by cobicistat versus ritonavir relative to plasma ...
Bartels, Hanni, Decosterd, Laurent, Battegay, Manuel, Laurent Decosterd, Marzolini, Catia, Hanni Bartels, Catia Marzolini, Manuel Battegay   +7 more
core   +1 more source

Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)-naïve and -experienced, virologically-suppressed adults living with HIV-1

HIV Research & Clinical Practice, 2021
Background Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated in AMBER (treatment-naïve adults; NCT02431247) and EMERALD (treatment-experienced, virologically-suppressed adults; NCT02269917). Objective
Gregory D. Huhn, Aimee Wilkin, Cristina Mussini, Christoph D. Spinner, John Jezorwski, Mohsine El Ghazi, Erika Van Landuyt, Erkki Lathouwers, Kimberley Brown, Bryan Baugh, on behalf of the AMBER and EMERALD study groups   +10 more
doaj   +1 more source